Systemic beta-interferon therapy for recurrent gliomas

A brief report

M. S. Mahaley, Edward Dropcho, L. Bertsch, T. Tirey, G. Y. Gillespie

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recombinant beta-interferon in escalating dosages was administered intravenously three times weekly to seven patients with recurrent gliomas. No evidence of response was seen in any patient, either on neurological examination or by computerized tomography (CT). However, stabilization of tumor volume, assessed from contrast-enhanced CT scans, occurred for 8 to 26 weeks in three patients. Immediate progression of disease despite treatment occurred in four patients.

Original languageEnglish (US)
Pages (from-to)639-641
Number of pages3
JournalJournal of Neurosurgery
Volume71
Issue number5 I
StatePublished - 1989
Externally publishedYes

Fingerprint

Interferon-beta
Glioma
Tomography
Neurologic Examination
Therapeutics
Tumor Burden
Disease Progression

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Mahaley, M. S., Dropcho, E., Bertsch, L., Tirey, T., & Gillespie, G. Y. (1989). Systemic beta-interferon therapy for recurrent gliomas: A brief report. Journal of Neurosurgery, 71(5 I), 639-641.

Systemic beta-interferon therapy for recurrent gliomas : A brief report. / Mahaley, M. S.; Dropcho, Edward; Bertsch, L.; Tirey, T.; Gillespie, G. Y.

In: Journal of Neurosurgery, Vol. 71, No. 5 I, 1989, p. 639-641.

Research output: Contribution to journalArticle

Mahaley, MS, Dropcho, E, Bertsch, L, Tirey, T & Gillespie, GY 1989, 'Systemic beta-interferon therapy for recurrent gliomas: A brief report', Journal of Neurosurgery, vol. 71, no. 5 I, pp. 639-641.
Mahaley MS, Dropcho E, Bertsch L, Tirey T, Gillespie GY. Systemic beta-interferon therapy for recurrent gliomas: A brief report. Journal of Neurosurgery. 1989;71(5 I):639-641.
Mahaley, M. S. ; Dropcho, Edward ; Bertsch, L. ; Tirey, T. ; Gillespie, G. Y. / Systemic beta-interferon therapy for recurrent gliomas : A brief report. In: Journal of Neurosurgery. 1989 ; Vol. 71, No. 5 I. pp. 639-641.
@article{0f40ab95b0744c239927c4aefb48a771,
title = "Systemic beta-interferon therapy for recurrent gliomas: A brief report",
abstract = "Recombinant beta-interferon in escalating dosages was administered intravenously three times weekly to seven patients with recurrent gliomas. No evidence of response was seen in any patient, either on neurological examination or by computerized tomography (CT). However, stabilization of tumor volume, assessed from contrast-enhanced CT scans, occurred for 8 to 26 weeks in three patients. Immediate progression of disease despite treatment occurred in four patients.",
author = "Mahaley, {M. S.} and Edward Dropcho and L. Bertsch and T. Tirey and Gillespie, {G. Y.}",
year = "1989",
language = "English (US)",
volume = "71",
pages = "639--641",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "5 I",

}

TY - JOUR

T1 - Systemic beta-interferon therapy for recurrent gliomas

T2 - A brief report

AU - Mahaley, M. S.

AU - Dropcho, Edward

AU - Bertsch, L.

AU - Tirey, T.

AU - Gillespie, G. Y.

PY - 1989

Y1 - 1989

N2 - Recombinant beta-interferon in escalating dosages was administered intravenously three times weekly to seven patients with recurrent gliomas. No evidence of response was seen in any patient, either on neurological examination or by computerized tomography (CT). However, stabilization of tumor volume, assessed from contrast-enhanced CT scans, occurred for 8 to 26 weeks in three patients. Immediate progression of disease despite treatment occurred in four patients.

AB - Recombinant beta-interferon in escalating dosages was administered intravenously three times weekly to seven patients with recurrent gliomas. No evidence of response was seen in any patient, either on neurological examination or by computerized tomography (CT). However, stabilization of tumor volume, assessed from contrast-enhanced CT scans, occurred for 8 to 26 weeks in three patients. Immediate progression of disease despite treatment occurred in four patients.

UR - http://www.scopus.com/inward/record.url?scp=0024347330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024347330&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 639

EP - 641

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 5 I

ER -